Posted by Michael Wonder on 15 Dec 2021
Rinvoq (upadacitinib) receives U.S. FDA approval for active psoriatic arthritis
14 December 2021 - Milestone marks the second FDA approved indication for Rinvoq following rheumatoid arthritis in 2019.
AbbVie today announced that the U.S. FDA has approved Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor blockers.
